Viral Hepatitis
A real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir in the treatment of genotype 1b chronic hepatitis C
Liu Junping, Cheng Yongqian, Zhang Jiming, Jin Huiming, Ning huibin, Li kuan, Ma Mengyang, Wu Yanan, Peng Zhen, Yin Hui, Liu Cuiping, Shang Jia
Published 2018-12-20
Cite as Chin J Hepatol, 2018,26(12): 927-932. DOI: 10.3760/cma.j.issn.1007-3418.2018.12.010
Abstract
ObjectiveTo recognize the efficacy and safety of paritaprevir/ritonavir-ombitasvir combined with dasabuvir (OBV/PTV/RTV+DSV) in the treatment of genotype 1b chronic hepatitis C.
MethodsPatients with genotype 1b chronic hepatitis C who were admitted to the People's Hospital of Henan Province, Huashan Hospital of Shanghai and the Fifth Medical Center of the General Hospital of the People's Liberation Army of China between November 2017 to August 2018 were enlisted. All patients received OBV/PTV/RTV+DSV antiviral therapy. HCV RNA levels were measured at baseline, weeks 1, 2, 3, 4, 8, 12, and 24, then 12 weeks, and 24 weeks after completion of treatment; patients’ comorbidity, concomitant medications, and clinical adverse events were recorded.
Results108 patients were enrolled in the study, with an average age of 49.1 years, 44 patients were male (40.8%), 96.3% (104/108) were newly diagnosed, and four patients had previous treatment history, of whom three were treated with IFN and one with IFN + DAA. Ninety-eight cases completed 12 weeks treatment and 89 cases were in follow up for 12 weeks, after discontinuation of the drug. Overall, 89 cases (100%) achieved SVR12.One patient treated with PR and DAA had HCV RNA level of 869175 IU/mL at 4 weeks of treatment, which was significantly higher than the baseline HCV RNA level (301776IU/ML), and was judged as failure of treatment; and follow-up was discontinued. Of all enrolled patients, 19 (17.6%) had underlying diseases and 15 (13.9%) had combined medications. During treatment, adverse events (AE) occurred in 11 patients (10.1%). The main adverse events were pruritus and elevated bilirubin.
ConclusionCombined antiviral therapy (OBV/PTV/RTV+DSV) of 12 weeks are highly effective with good safety profile in the treatment of Chinese patients with genotype 1b chronic hepatitis C.
Key words:
Chronic hepatitis C; Therapy; Direct acting antiviral agents; OBV/PTV/RTV; DSV
Contributor Information
Liu Junping
Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
Cheng Yongqian
The Fifth Medical Center of the General Hospital of the Chinese people's Liberation Army, BeiJing, 100039, China
Zhang Jiming
Department of Infectious Diseases, Huashan Hospital Affiliated to Fudan University, Shanghai, 200040, China
Jin Huiming
Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
Ning huibin
Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
Li kuan
Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
Ma Mengyang
Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
Wu Yanan
Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
Peng Zhen
Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
Yin Hui
Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
Liu Cuiping
Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
Shang Jia
Department of Infectious Diseases, Henan Provincial People's Hospital, zhengzhou 450003, China
